New era in the fight against cancer: Evolution and cancer: Progress in tumour treatments

Authors

  • Ana Lluch Hernández University Hospital Clinic, Valencia (Spain).
  • José Alejandro Pérez-Fidalgo University Hospital Clinic, Valencia (Spain).
  • Paloma Martín Martorell University Hospital Clinic, Valencia (Spain).

DOI:

https://doi.org/10.7203/metode.78.2469

Keywords:

targeted therapies, anti-target drugs, tyrosine kinase inhibitors, resistance mechanisms, screening

Abstract

In recent decades, oncohematology has witnessed major advances in cancer treatment and survival. The toxicity associated with classical chemotherapy, and the need to improve the efficacy and tolerance to treatment, have led to a flood of research activity and many fruitful results. Much of this effort has been focused on developing «targeted therapies» directed against specific functional alterations, which are key to tumour cell survival. Thus, greater treatment efficacy is sought whilst the patient pays a lower cost in terms of toxicity. Advances in other fields of oncology and epidemiology, surgery and radiation therapy have also contributed to the constant advancement of oncology. In short, we glimpse a future ahead that is full of hope for cancer patients and, at the same time, exciting for physicians and researchers alike.

Downloads

Download data is not yet available.

Author Biographies

Ana Lluch Hernández, University Hospital Clinic, Valencia (Spain).

Head of the Oncology and Haematology Unit. University Hospital Clinic, Valencia (Spain).

José Alejandro Pérez-Fidalgo, University Hospital Clinic, Valencia (Spain).

Doctor. Oncology and Haematology Unit. University Hospital Clinic, Valencia (Spain).

Paloma Martín Martorell, University Hospital Clinic, Valencia (Spain).

Doctor. Oncology and Haematology Unit. University Hospital Clinic, Valencia (Spain).

References

Arora, A. and E. M. Scholar, 2005. «Role of Tyrosine Kinase Inhibitors in Cancer Therapy». The Journal of Pharmacology and Experimental Therapeutics, 315: 971-979. DOI: <10.1124/jpet.105.084145>.

Berry, D. et al., 2005. «Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer». The New England Journal of Medicine, 353: 1784-1792. DOI: <10.1056/NEJMoa050518>.

Calvo, A., 2006. «Ehrlich y el concepto de “bala mágica”». Revista Española de Quimioterapia, 19: 90-92.

Fernández-Velilla Peña, M. et al., 2013. «Tratamiento de lesiones pulmonares mediante radioterapia estereotáxica extracraneal tras colocación guiada por tomografía computarizada de marcador Viscoil®: experiencia inicial». Radiología, 55(3): 225-232. DOI: <10.1016/j.rx.2011.09.020>.

Pass, H. et al., 2004. «Changes in Management Techniques and Patterns of Disease Recurrence over Time in Patients with Breast Carcinoma Treated with Breast-conserving Therapy at a Single Institution». Cancer, 101(4): 713-720. DOI: <10.1002/cncr.20410>.

Roth, B. J. et al., 2013. «Clinical Cancer Advances in 2012: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology». Journal of Clinical Oncology, 31(1): 131-161. DOI: <10.1200/JCO.2012.47.1938>.

Published

2014-06-01

How to Cite

Lluch Hernández, A., Pérez-Fidalgo, J. A., & Martín Martorell, P. (2014). New era in the fight against cancer: Evolution and cancer: Progress in tumour treatments. Metode Science Studies Journal, (4), 101–105. https://doi.org/10.7203/metode.78.2469
Metrics
Views/Downloads
  • Abstract
    549
  • PDF
    146
  • PDF (Català/Valencià)
    117
  • PDF (Español)
    200

Issue

Section

In light of evolution. Making sense of biotech applications

Metrics

Similar Articles

> >> 

You may also start an advanced similarity search for this article.